Brett A. Postal

Brett A. Postal is a patent litigation attorney with a focused practice in chemical, pharmaceutical, biological, and life science technologies, particularly in Hatch-Waxman cases. He represents clients primarily on the defendant side, as evidenced by his tracked appearances in two cases defending against pharmaceutical patent infringement claims.

Mr. Postal is a Member at Rothwell Figg Ernst & Manbeck, where he has practiced since joining the firm in 2007 and was named partner in 2019. His work encompasses a broad spectrum of intellectual property matters, including patent litigation in district and appellate courts, client counseling, patent prosecution, and opinion work. He is admitted to practice in Washington, D.C.

His notable representations include defending Celltrion, Inc. against Regeneron Pharmaceuticals, Inc., where Regeneron ultimately disclaimed all claims of a challenged patent following Celltrion's Post-Grant Review petition. He also represents Amgen Inc. in multidistrict litigation initiated by Regeneron Pharmaceuticals, Inc., involving aflibercept patents, which saw a district court deny Regeneron's preliminary injunction motion, a decision affirmed by the Federal Circuit.

Mr. Postal possesses extensive experience with post-grant proceedings, routinely handling parallel proceedings before the Patent Trial and Appeal Board (PTAB) and federal courts. He is an editor and author for Rothwell Figg's PTAB Law Blog, contributing analysis on PTAB decisions and Federal Circuit appellate rulings concerning inter partes review (IPR) proceedings.